On Wednesday, Shares of Texas Instruments Inc. (NASDAQ:TXN), lost -1.85% to $49.30.
Texas Instruments Incorporated, stated second-quarter revenue of $3.23 billion, net income of $696 million and earnings per share of 65 cents.
Regarding the company’s performance and returns to shareholders, Rich Templeton, TI’s chairman, president and CEO, made the following comments:
- “Revenue declined 2 percent year over year, inclusive of notably weak demand in communications equipment and continued strong demand in automotive.
- “Even so, our core businesses of Analog and Embedded Processing, together, grew slightly year over year and comprised 85 percent of second-quarter revenue. Analog delivered its eighth successive quarter of year-over-year growth.
- “Gross margin of 58.2 percent was up 1 percentage point from a year ago, reflecting the diversity and longevity of our product portfolio, in addition to the efficiency of our manufacturing strategy.
- “Our cash flow from operations once again underscored the strength of our business model. Free cash flow for the trailing 12 months was up 13 percent from a year ago to $3.6 billion, or 27 percent of revenue. This represents an enhance of 2 percentage points from a year ago and is consistent with our targeted range of 20-30 percent of revenue.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing.
Shares of Gilead Sciences Inc. (NASDAQ:GILD), declined -0.29% to $117.44, during its last trading session.
Gilead Sciences, declared detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational once-daily single tablet regimen (STR) of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate (TDF)-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically noteworthy improvements in bone and renal laboratory parameters. These data were presented in an oral session (session TUAB0102) at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention (IAS) in Vancouver, Canada.
In November 2014, Gilead filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for E/C/F/TAF, the first investigational once-daily TAF-based STR. TAF is an investigational novel nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread® (TDF), in addition to improved renal and bone laboratory parameters as contrast to TDF in earlier clinical trials in combination with other antiretroviral agents.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific.
Finally, Fidelity National Information Services, Inc. (NYSE:FIS), ended its last trade with 0.52% gain, and closed at $64.13.
Combining deep industry and trust experience with market-leading technology, FIS™ (FIS), a global leader in banking and payments technology as well as consulting and outsourcing solutions, has extended its long-term relationship with INTRUST Bank through the addition of trust operations outsourcing and wealth administration technology.
FIS continues to capitalize on market demand for deep domain expertise plus complete back-office support. Having attained Reliance Trust last year, FIS empowers the market with one of the most flexible outsourcing solution sets in the trust and wealth administration industry.
Those efficiencies – particularly when paired with FIS’ industry experience – have improved traditional trust operations, allowing firms to consolidate technology and streamline operations. This was especially important to INTRUST Bank as it focuses on delivering deeply personal service to its customers and required a partner that shares its customer-focused culture. INTRUST selected FIS for trust and investment processing, trust operations outsourcing – counting custody and mutual fund clearing services – and a number of additional solutions.
Fidelity National Information Services, Inc. provides banking and payments technology, consulting, and outsourcing solutions worldwide. Its Financial Solutions Group segment offers core processing software applications to run banking processes; retail banking delivery applications that enable financial institutions to integrate and streamline customer-facing operations and back-office processes; fraud, risk administration, and compliance solutions; syndicated loan applications that support wholesale and commercial banking operations; and onshore and offshore commercial services, such as consulting engagements, application development projects, operations support, and infrastructure administration, in addition to integrated consulting and advisory, technology, and IT transformation services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
